glp 1 dizzy Balance Disorders Archives GLP-1 drugs tied to elevated

Electrolytes (sodium, potassium, magnesium): To support hydration, especially for those experiencing nausea, vomiting, or reduced fluid intake

The SURMOUNT 4 is a trial to assess the effects of tirzepatide, a dual receptor agonist targeting GLP-1 and GIP, on long-term weight reduction over 2 years in those without diabetes

both arms included lifestyle modifications

Compared to traditional antidiabetic drugs, GLP-1 RAs showed no statistically significant differences in nasopharyngitis, headache, lipase increased and dyspepsia while showed higher risk of nausea and vomiting

Glucagon-Like Peptide-1 Receptor Agonists During Pregnancy and Lactation

In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 1622.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46]